Through a series of clinical, cellular, molecular, and in vivo analyses, our study provides the first evidence that the phospholipid transporter PITPNC1 stands as a functional KRAS effector in LUAD and PDAC, further confirming the critical role of the phospholipid transport machinery in cancers driven by the KRAS oncogene. Here, KRAS is linked to cancer.